JP2009508521A - タンパク凝集に関連する疾患の診断予防及び治療のためのｖｈｈ - Google Patents

タンパク凝集に関連する疾患の診断予防及び治療のためのｖｈｈ Download PDF

Info

Publication number
JP2009508521A
JP2009508521A JP2008532177A JP2008532177A JP2009508521A JP 2009508521 A JP2009508521 A JP 2009508521A JP 2008532177 A JP2008532177 A JP 2008532177A JP 2008532177 A JP2008532177 A JP 2008532177A JP 2009508521 A JP2009508521 A JP 2009508521A
Authority
JP
Japan
Prior art keywords
vhh
antigen
protein
selection
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009508521A5 (https=
Inventor
コルネリス テオドルス フェリップス
デル マーレル シルヴェレ マリア ファン
ペーター フェルヘーセン
フルシク ダヴィッド ルティエ
オーメン ハリティアン バウデウィン ファン
Original Assignee
アカデミッシュ ジーケンハイス レイデン
ユニヴェルシテイト ユトレヒト ホールディング ベースローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アカデミッシュ ジーケンハイス レイデン, ユニヴェルシテイト ユトレヒト ホールディング ベースローテン フェンノートシャップ filed Critical アカデミッシュ ジーケンハイス レイデン
Publication of JP2009508521A publication Critical patent/JP2009508521A/ja
Publication of JP2009508521A5 publication Critical patent/JP2009508521A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008532177A 2005-09-23 2006-09-25 タンパク凝集に関連する疾患の診断予防及び治療のためのｖｈｈ Pending JP2009508521A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05077180 2005-09-23
PCT/NL2006/000475 WO2007035092A2 (en) 2005-09-23 2006-09-25 Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates

Publications (2)

Publication Number Publication Date
JP2009508521A true JP2009508521A (ja) 2009-03-05
JP2009508521A5 JP2009508521A5 (https=) 2009-11-05

Family

ID=35700351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008532177A Pending JP2009508521A (ja) 2005-09-23 2006-09-25 タンパク凝集に関連する疾患の診断予防及び治療のためのｖｈｈ

Country Status (6)

Country Link
US (1) US20100323905A1 (https=)
EP (1) EP1934611A2 (https=)
JP (1) JP2009508521A (https=)
AU (1) AU2006292871A1 (https=)
CA (1) CA2622968A1 (https=)
WO (1) WO2007035092A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160102971A (ko) * 2013-11-13 2016-08-31 에프. 호프만-라 로슈 아게 올리고펩티드 및 그 결합체를 생산하는 방법
JP2019210267A (ja) * 2018-06-08 2019-12-12 パナソニックＩｐマネジメント株式会社 Ｖｈｈ抗体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
PT2491056T (pt) 2009-10-22 2021-10-26 Univ Of Twente Vhh para aplicação na reparação de tecidos, regeneração de órgãos, substituição de órgãos e engenharia de tecidos
UY33253A (es) * 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
SG2014010482A (en) * 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
CN109206519B (zh) * 2018-09-21 2021-12-03 成都阿帕克生物科技有限公司 一种抗尿素酶b亚单位的纳米抗体及核酸分子和应用
CA3174330A1 (en) * 2021-03-31 2022-09-30 Shugang YAO Binding agents targeting tumors and/or immune cells
CN121511255A (zh) * 2023-05-17 2026-02-10 奥德赛治疗股份有限公司 经修饰的单结构域抗体
TW202543670A (zh) * 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037681A2 (en) * 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813276A (pt) * 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
AUPR546801A0 (en) * 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037681A2 (en) * 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160102971A (ko) * 2013-11-13 2016-08-31 에프. 호프만-라 로슈 아게 올리고펩티드 및 그 결합체를 생산하는 방법
JP2017503475A (ja) * 2013-11-13 2017-02-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アミロイドβを指向するラクダ科動物単一ドメイン抗体及びその接合体を製造する方法
KR102306065B1 (ko) 2013-11-13 2021-09-29 에프. 호프만-라 로슈 아게 올리고펩티드 및 그 결합체를 생산하는 방법
JP2019210267A (ja) * 2018-06-08 2019-12-12 パナソニックＩｐマネジメント株式会社 Ｖｈｈ抗体
JP7122672B2 (ja) 2018-06-08 2022-08-22 パナソニックＩｐマネジメント株式会社 Ｖｈｈ抗体

Also Published As

Publication number Publication date
US20100323905A1 (en) 2010-12-23
AU2006292871A1 (en) 2007-03-29
WO2007035092A2 (en) 2007-03-29
CA2622968A1 (en) 2007-03-29
WO2007035092A3 (en) 2007-07-12
EP1934611A2 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
Verheesen et al. Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation
JP6670275B2 (ja) 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体
US20210347855A1 (en) Synthetic Single Domain Antibody
US20200308265A1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
JP2009508521A (ja) タンパク凝集に関連する疾患の診断予防及び治療のためのｖｈｈ
KR102806328B1 (ko) 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
JP7212391B2 (ja) ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
KR20080090408A (ko) 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
JP2016026207A (ja) 抗脈管形成療法のための二重特異性結合分子
TW200844110A (en) Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
KR20120115217A (ko) Ｄｌｌ４－결합 분자
AU2004293180A1 (en) Antibodies binding to a C-terminal fragment of Apolipoprotein E
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
KR20100074181A (ko) β-아밀로이드 펩티드에 대한 인간화 항체
WO2022058591A2 (en) Sars-cov-2-nanobodies
US12509505B2 (en) Anti Tau SVQIVYKPV epitope single domain antibody
KR102163465B1 (ko) 라이실 tRNA 합성효소 N-말단에 특이적으로 결합하는 항체를 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
Medecigo et al. Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries
JP2022502369A (ja) α−シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
JP7814714B2 (ja) ロイシンリッチリピートキナーゼ２のアロステリック調節因子
KR20250116724A (ko) 항-헌팅틴 항체
Wavreil et al. Development of a novel VHH intrabody targeting the N17 region of huntingtin exon 1 protein that prevents inclusion body formation.
WO2023034842A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024177998A2 (en) Human aggregated tau binding molecules
JP2023169439A (ja) 抗ヒトｔｒｐｖ２抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120910